drugset
drugset / Trial / NCT00005811

Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment

NCT00005811 ↗

Phase 2 Completed 77 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. This phase II trial is studying how well topotecan hydrochloride works in treating children with meningeal cancer that has not responded to previous treatment

Timeline

Start
2000-04
Primary completion
2006-04
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Topotecan Small molecule — Intrathecal

Indications

AIDS-related primary central nervous system lymphoma Burkitt lymphoma Hodgkins lymphoma childhood acute lymphoblastic leukemia childhood acute myeloid leukemia childhood medulloblastoma diffuse large B-cell lymphoma immunodeficiency-associated lymphoproliferative disease large-cell immunoblastic lymphoma neoplastic meningitis